Sarda SP, Heyes A, Bektas M, Thankur T, Chao W, Intorcia M, Wronski S, Jones DL. Humanistic and economic burden of geographic atrophy: a systematic literature review. Clin Opththa. 2021 Dec 8;2021(15):4629-44.
Ng X, Stothers S, Mansfield C, Poulos C, Peay H, Lee TS, Irony T, Ho M. Adaptation of the Western Ontario McMaster Universities (WOMAC) osteoarthritis index for use in a patient preference study to inform regulatory decision-making. Poster presented at the 2021 SMDM Virtual Annual Meeting; October 19, 2021.
Kupperman BD, Keyloun KR, Campbell JH, Zhou X, Davenport E, Bakri SJ. Decreased vision improvement in DME eyes with longer duration or larger amounts of excess edema: a post-hoc analysis of protocol T. Presented at the 2021 54th Retina Society Annual Scientific Meeting; September 29, 2021. Chicago, IL.
Jones DL, Bektas M, Heyes A, Wronski S, Sarda SP. Clinical & humanistic burden of geographic atrophy (GA). Poster presented at the 2021 EURETINA Virtual Congress; September 9, 2021.
Ho M, Gonzalez JM, Mansfield C, Wilson L. Three preference studies sponsored by FDA CBER to inform benefit-risk assessment for biologics. Presented at the Virtual ISPOR 2021 Conference; May 20, 2021.
Samuelson TW, Singh IP, Williamson BK, Falvey H, Lee WC, Odom D, McSorley D, Katz LJ. Quality of life in primary open-angle glaucoma and cataract: an analysis of VFQ-25 and OSDI from the iStent inject® Pivotal Trial. Am J Ophthalmol. 2021 Mar 15;229:220-9. doi: 10.1016/j.ajo.2021.03.007
Zografos L, Rivero-Ferrer E, Abramsky S, Lou J, Davenport E, Wolin D. Evaluation of the physician education component of the ozurdex risk management plan. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Gonzalez Sepulveda JM, Irony T, Mansfield C, Wilson L. Stated preferences to inform benefit-risk assessment for biologics-three FDA-sponsored studies. Presented at the 2020 ISPOR Virtual Conference; May 18, 2020.